Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2

• Gonzalo Godoy J ^[1] ; Vicente Gutiérrez ^[3] ; Mario Montecinos ^[2] ; Alejandro Yenes ^[4]
  1. [1] Hospital del Salvador

     Hospital del Salvador

     Santiago, Chile

     
  2. [2] Universidad Diego Portales

     Universidad Diego Portales

     Santiago, Chile

     
  3. [3] Clínica Avansalud
  4. [4] Centro Médico Cardionew

  Mostrar afiliaciones +
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 143, Nº. 1, 2015, págs. 63-68
• Idioma: español
• Títulos paralelos:
  • Safety and efficacy of Vildagliptin in real life Chilean diabetic patients
• Enlaces
  • Texto completo
• Resumen

  • Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known. Aim: To assess the safety profile and effectiveness of 12 weeks of treatment with Vildagliptin for glycemic control in T2D Chilean patients with a poor glycemic control. Patients and Methods: Retrospective assessment of the effects of Vildagliptin treatment during 12 weeks in 103 T2D patients aged 29 to 92 years (47% males). The main outcomes were changes in glycosylated hemoglobin and the occurrence of adverse effects. Results: After 12 weeks of Vildagliptin use, glycosylated hemoglobin decreased from 8.3 ± 1.4 to 7.2 ± 1.1% (p < 0.01). Fasting plasma glucose and the number of hypoglycemic events also decreased significantly. No significant weight change was observed. The treatment had good compliance, tolerance and patient satisfaction. Conclusions: Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and was well tolerated in this group of diabetic patients.